International Validation Study for Interim PET in ABVD-Treated, Advanced-Stage Hodgkin Lymphoma: Interpretation Criteria and Concordance Rate Among Reviewers

  title={International Validation Study for Interim PET in ABVD-Treated, Advanced-Stage Hodgkin Lymphoma: Interpretation Criteria and Concordance Rate Among Reviewers},
  author={Alberto Biggi and Andrea Gallamini and St{\'e}phane Chauvie and Martin Hutchings and Lale Kostakoglu and Michele Gregianin and Michel Meignan and Bogdan Małkowski and Michael S. Hofman and Sally F. Barrington},
  journal={The Journal of Nuclear Medicine},
  pages={683 - 690}
At present, there are no standard criteria that have been validated for interim PET reporting in lymphoma. In 2009, an international workshop attended by hematologists and nuclear medicine experts in Deauville, France, proposed to develop simple and reproducible rules for interim PET reporting in lymphoma. Accordingly, an international validation study was undertaken with the primary aim of validating the prognostic role of interim PET using the Deauville 5-point score to evaluate images and… 

Figures and Tables from this paper

Comparison Between Different PET and CT-Based Imaging Interpretation Criteria at Interim Imaging in Patients With Diffuse Large B-Cell Lymphoma

The predictive value of iPET in DLBCL patients is most reliable using the Deauville and PERCIST criteria, and criteria that rely on anatomical characteristics, namely, RECIST and IHP criteria, are less accurate in predicting patient outcomes inDLBCL.

The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale

The prognostic role and validity of the Deauville five-point scale for interpretation of interim positron emission tomography scans have been confirmed by the present study.

Prognostic Value of Interim FDG-PET in Diffuse Large Cell Lymphoma: Results from the CALGB 50303 Clinical Trial.

As part of a randomized, prospective clinical trial in large cell lymphoma, we conducted serial FDG-PET at baseline, after two cycles of chemotherapy (i-PET), and at end of treatment (EoT) to

Inter-Reader Reliability of Early FDG-PET/CT Response Assessment Using the Deauville Scale after 2 Cycles of Intensive Chemotherapy (OEPA) in Hodgkin’s Lymphoma

Inter-reader reliability of the five point D-scale is poor in this interobserver analysis of paediatric patients who underwent OEPA, and inter-reader variability is maximal in cases assigned to D2 or D3.

Interim 18F-FDG PET SUVmax Reduction Is Superior to Visual Analysis in Predicting Outcome Early in Hodgkin Lymphoma Patients

A semiquantitative approach using maximum standardized uptake value (SUVmax) reduction between baseline and interim PET was shown to be superior to the 5-point scale in patients with diffuse large B-cell lymphoma and may also improve the accuracy of interim PET interpretation in HL.

Prognostic Value of Bone Marrow Tracer Uptake Pattern in Baseline PET Scans in Hodgkin Lymphoma: Results from an International Collaborative Study

It is confirmed that 18F-FDG PET scanning is a reliable tool for BMI assessment in HL, and BM biopsy is no longer needed for routine staging, and the interobserver agreement for BMI in this study proved excellent and only focal 18F -FDG BM uptake should be considered as a harbinger of HL.

Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe)

IMPeTUs criteria proved highly reproducible and could therefore be considered as a base for harmonizing PET interpretation in multiple myeloma and a prospective clinical validation of IMPeT Us criteria is underway.

Head and neck PET/CT therapy response interpretation criteria (Hopkins criteria) - external validation study.

External validation of Hopkins criteria showed excellent inter-reader agreement and prediction of PFS in HNSCC patients.

PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study.

Results confirm PET-CT as the modern standard for staging HL and that response assessment using Deauville criteria is robust, enabling translation of RATHL results into clinical practice.

Quantitative analysis of basal and interim PET/CT images for predicting tumor recurrence in patients with Hodgkin’s lymphoma

The novel tool enables estimation of the risk of tumor relapse after chemotherapy in HL patients on the basis of basal and interim PET/CT scans including SUV and densitometric information.



Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma

The criteria developed for reporting in the RATHL trial are sufficiently robust to be used in a multicentre setting.

Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study.

The data, showing only moderate reproducibility among nuclear medicine experts, indicate the need to standardize PET interpretation in research and practice.

Dual-point FDG-PET: A novel scanning technique in Hodgkin lymphoma with bulky disease.

Preliminary results from a cohort of HL patients presenting with bulky lesions, scanned with 2P-PET with the aim to increase specificity and PPV are reported.

18F-FDG PET After 2 Cycles of ABVD Predicts Event-Free Survival in Early and Advanced Hodgkin Lymphoma

A negative interim 18F-FDG PET result is highly predictive of treatment success in overall HL patients, as well as in subgroups of patients with early or advanced-stage disease and with low or high IPS risk.

Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review.

  • T. TerasawaJ. Lau H. Nagai
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
For low- to intermediate-risk advanced-stage HL, FDG-PET performed after a few cycles of standard chemotherapy seems to be a reliable prognostic test to identify poor responders, warranting prospective studies to assess PET-based treatment strategies.

Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study.

PET-2 overshadows the prognostic value of IPS and emerges as the single most important tool for planning of risk-adapted treatment in advanced HL.

Revised response criteria for malignant lymphoma.

  • B. ChesonB. Pfistner V. Diehl
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2007
New guidelines incorporating PET, IHC, and flow cytometry for definitions of response in non-Hodgkin's and Hodgkin's lymphoma are presented and it is hoped that they will be adopted widely by study groups, pharmaceutical and biotechnology companies, and regulatory agencies to facilitate the development of new and more effective therapies to improve the outcome of patients with lymphoma.

The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease.

18F-FDG-PET scan performed after two courses of conventional standard-dose chemotherapy in advanced-stage Hodgkin's disease was able to predict treatment outcome in 103/108 (95%) of the patients, and the positive predictive value of a PET-2 was 90% and the negative predictive value was 97%.

Report on the First International Workshop on interim-PET scan in lymphoma

The aim of the workshop was to reach a consensus on simple, reproducible criteria for interim-PET interpretation in Hodgkin lymphoma and diffuse large B-cell lymphoma, and to launch two or more international validation studies, in an attempt to validate these rules.

Development and application of a real-time on-line blinded independent central review of interim PET scans to determine treatment allocation in lymphoma trials.

  • M. MeignanE. Itti M. André
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
This patient may not be the third reported instance of TLS caused by radiotherapy because three patients had already been cited in his report, but only adult patients were included in the report, and Gemici mentioned that the daily fractionated dose in addition to total dose should also be considered.